Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis

2015249 citationsReviewhybrid Open Access

Authors

Kevin Winthrop · Oregon Health & Science University

S. H. Park · The Catholic University of Korea Seoul St. Mary's Hospital

Ahmet Gül · Istanbul University

Myrna Cardiel · Universidad de Morelia

Juan J. Gómez‐Reino · Complejo Hospitalario Universitario de Santiago

Yoshiya Tanaka · University of Occupational and Environmental Health Japan

Kenneth Kwok

Abstract

Within the global tofacitinib RA development programme, TB was the most common OI reported but was rare in regions of low and medium TB incidence. Patients who screen positive for latent TB can be treated with isoniazid during tofacitinib therapy.

Topics & Keywords

Tuberculosis Research and Epidemiology Mycobacterium research and diagnosis Chronic Lymphocytic Leukemia Research

UN Sustainable Development Goals

Partnerships for the goals

Publication Details

Published in: Annals of the Rheumatic Diseases

Volume 75, Issue 6, pp. 1133-1138

DOI: 10.1136/annrheumdis-2015-207319

Field-Weighted Citation Impact: 9.72